相关实验视频

Updated: Jul 5, 2025

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Preparation and Characterization of SDF-1α-Chitosan-Dextran Sulfate Nanoparticles

Published on: January 22, 2015

一种水溶性基托衍生物,用于释放生物活性德费洛克萨

Georgia Michailidou¹, Yupeng Li^2,3, Alexandra Zamboulis¹

¹Laboratory of Polymer and Colors Chemistry and Technology, Department of Chemistry, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.

International journal of molecular sciences

|January 23, 2024

概括

新的碳氧甲基基托 (CMCS) 纳米颗粒有效地提供铁化剂deferoxamine (DFO),改善细胞缺铁治疗. 这些纳米粒子提供持续的药物释放,以提高治疗潜力.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

德菲洛克萨 (DFO) 对于管理铁过载至关重要,但细胞透性差,半衰期短,需要复杂的管理.
素 (CS) 纳米颗粒此前已开发用于持续的DFO释放,显示了改善药物输送的希望.

研究的目的:

开发和评估碳甲基 (CMCS) 固体分散和纳米颗粒,用于增强德胺 (DFO) 封装和控制释放.
将基于CMCS的DFO配方与传统的CS纳米颗粒的特性和体外性能进行比较.

主要方法:

使用三酸盐 (TPP) 进行离子转化凝制备DFO装载的CS和CMCS纳米粒子和分散物.
使用FTIR进行DFO封装的表征,并使用X射线衍射 (XRD) 和微分扫描热度计 (DSC) 评估药物的晶度和状态.
在48小时内进行体外药物释放研究,并对RAW 264.7巨细胞和HeLa细胞进行细胞分析,以评估铁化效应.

主要成果:

FTIR证实了成功地将DFO纳入CMCS纳米粒子和分散剂.
XRD和DSC表明,CMCS纳米粒子促进了DFO的无形状态,而分散降低了其结晶性.
实验室释放显示从CS (48h) 和CMCS (24h) 纳米粒子中持续释放DFO.
在细胞培养中使用CMCS-DFO治疗诱导了转移素受体1mRNA和抑制了费里丁,证明了有效的细胞铁化.

结论:

CMCS-DFO纳米颗粒提供了一个有效的系统,用于输送生物活性deferoxamine,改善细胞铁化.
这些新型纳米粒子代表了治疗与铁过载和细胞铁失调相关的疾病的有希望的进步.

关键词:

在β-thalassemia中发生的.基多酸盐的使用方法德菲罗克萨明是一种素.药物释放释放药物释放药物释放的时间纳米颗粒是一种纳米粒子.固体分散的散发方式持续释放可以维持释放.

更多相关视频

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

A Freeze-Thawing Method to Prepare Chitosan-Polyvinyl alcohol Hydrogels Without Crosslinking Agents and Diflunisal Release Studies

A Freeze-Thawing Method to Prepare Chitosan-Polyvinyl alcohol Hydrogels Without Crosslinking Agents and Diflunisal Release Studies

Published on: January 14, 2020

相关概念视频

Extraction: Advanced Methods

Extraction: Advanced Methods

Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...

Masking and Demasking Agents

Masking and Demasking Agents

EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...

Depolarizing Blockers: Pharmocokinetics

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...